1 Min Read
July 6 (Reuters) - Revive Therapeutics Ltd
* Revive therapeutics Ltd. announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria Source text for Eikon: Further company coverage: )
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.